About Biotheus
Biotheus is a company based in Zhuhai (China) founded in 2018 by Xiaolin Liu and Joanne Sun was acquired by BioNTech in November 2024. Biotheus has raised $14.53 million across 4 funding rounds from investors including BioNTech, General Atlantic and IDG Capital. Biotheus operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter Zhuhai, China
- Founders Xiaolin Liu, Joanne Sun
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Biotheus
Biotheus has successfully raised a total of $14.53M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biotheus
Biotheus has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include BioNTech, General Atlantic and IDG Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity fund focused on global markets
|
Locked | Locked | Locked | |
|
Venture capital firm
|
Locked | Locked | Locked | |
|
Private equity and early-stage venture capital firm investing primarily in Chinese companies
|
Locked | Locked | Locked |
Investor details for Biotheus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biotheus
Investment portfolio details for Biotheus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biotheus
Detailed financials for Biotheus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biotheus Comparisons
Peer comparison for Biotheus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biotheus
Biotheus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
Detailed competitors of Biotheus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biotheus
Complete news archive for Biotheus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biotheus
Biotheus was founded in 2018.
Biotheus is headquartered in Zhuhai, China. It is registered at Zhuhai, Guangdong, China.
Xiaolin Liu is the current CEO of Biotheus. They have also founded this company.
Biotheus is a funded company, having raised a total of $14.53M across 4 funding rounds to date.
Developer of antibody-based therapeutics for cancer treatment. The companys candidates include PM8001, PM8003, PM1003, PM 1008, PM 1011, and PM1016 for cancer treatment.
Biotheus's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
Biotheus has 10 investors. Key investors include BioNTech, General Atlantic, IDG Capital, Highlight Capital, and Cowin Capital.